Phoremost

PhoreMost is a Cambridge-based biotechnology company developing small-molecule cancer therapies. Its lead programme, PMC-001, is described as an orally bioavailable, CNS-penetrant microtubule disruptor for primary and metastatic brain cancers, and the company is advancing it toward Phase 1/2a clinical evaluation. The pipeline also includes PMC-002 for HPV+ cancers, PMC-003 (a bifunctional degrader), and work on multiple E3 ligases for targeted protein degradation.

The company develops its own drug candidates and has collaborated with Boehringer Ingelheim on a Target Discovery Alliance, with milestones announced in 2023 and 2024. Its news page reports a Series B financing extended to $50M in September 2024 and the appointment of a Chief Medical Officer in June 2026. It states that it is interested in partnering with collaborators.

The registered company is PHOREMOST LIMITED, founded in 2014 and based in Cambridge, UK. Its office is at the Babraham Research Campus in Cambridge. The leadership team includes a CEO, CSO, CMO and CFO, and a board with a scientific advisory board.

Product: PMC-001, an orally bioavailable, CNS-penetrant microtubule disruptor in clinical preparation for brain cancers, with further pipeline candidates.